Silverfin false false 28/02/2026 01/03/2025 28/02/2026 Dr S Sparkes 05 August 2026 no description of principal activity 13179012 2026-02-28 13179012 2025-02-28 13179012 core:CurrentFinancialInstruments 2026-02-28 13179012 core:CurrentFinancialInstruments 2025-02-28 13179012 core:ShareCapital 2026-02-28 13179012 core:ShareCapital 2025-02-28 13179012 core:RetainedEarningsAccumulatedLosses 2026-02-28 13179012 core:RetainedEarningsAccumulatedLosses 2025-02-28 13179012 core:OfficeEquipment 2025-02-28 13179012 core:ComputerEquipment 2025-02-28 13179012 core:OfficeEquipment 2026-02-28 13179012 core:ComputerEquipment 2026-02-28 13179012 core:CostValuation 2025-02-28 13179012 core:CostValuation 2026-02-28 13179012 2025-03-01 2026-02-28 13179012 bus:FilletedAccounts 2025-03-01 2026-02-28 13179012 bus:SmallEntities 2025-03-01 2026-02-28 13179012 bus:AuditExemptWithAccountantsReport 2025-03-01 2026-02-28 13179012 bus:PrivateLimitedCompanyLtd 2025-03-01 2026-02-28 13179012 bus:Director1 2025-03-01 2026-02-28 13179012 core:OfficeEquipment core:TopRangeValue 2025-03-01 2026-02-28 13179012 core:ComputerEquipment core:TopRangeValue 2025-03-01 2026-02-28 13179012 2024-03-01 2025-02-28 13179012 core:OfficeEquipment 2025-03-01 2026-02-28 13179012 core:ComputerEquipment 2025-03-01 2026-02-28 iso4217:GBP xbrli:pure

Company No: 13179012 (England and Wales)

RAPTOR MEDICAL LIMITED

Unaudited Financial Statements
For the financial year ended 28 February 2026
Pages for filing with the registrar

RAPTOR MEDICAL LIMITED

Unaudited Financial Statements

For the financial year ended 28 February 2026

Contents

RAPTOR MEDICAL LIMITED

STATEMENT OF FINANCIAL POSITION

As at 28 February 2026
RAPTOR MEDICAL LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 28 February 2026
Note 2026 2025
£ £
Fixed assets
Tangible assets 3 1,146 2,400
Investments 4 120 120
1,266 2,520
Current assets
Cash at bank and in hand 305,496 247,308
305,496 247,308
Creditors: amounts falling due within one year 5 ( 2,729) ( 2,458)
Net current assets 302,767 244,850
Total assets less current liabilities 304,033 247,370
Net assets 304,033 247,370
Capital and reserves
Called-up share capital 100 100
Profit and loss account 303,933 247,270
Total shareholder's funds 304,033 247,370

For the financial year ending 28 February 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of Raptor Medical Limited (registered number: 13179012) were approved and authorised for issue by the Director. They were signed on its behalf by:

Dr S Sparkes
Director

05 August 2026

RAPTOR MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 28 February 2026
RAPTOR MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 28 February 2026
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Raptor Medical Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 1 The Atrium Phoenix Square, Wyncolls Road, Colchester, CO4 9AS, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Dividend income

Dividend income from investments is recognised when the shareholders' rights to receive payment have been established (provided that it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably).

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Office equipment 4 years straight line
Computer equipment 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Income Statement as described below.

Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value through profit or loss if the shares are publicly traded or their fair value can otherwise be measured reliably. Other investments are measured at cost less impairment.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

2. Employees

2026 2025
Number Number
Monthly average number of persons employed by the Company during the year, including the director 1 1

3. Tangible assets

Office equipment Computer equipment Total
£ £ £
Cost
At 01 March 2025 100 5,098 5,198
At 28 February 2026 100 5,098 5,198
Accumulated depreciation
At 01 March 2025 77 2,721 2,798
Charge for the financial year 23 1,231 1,254
At 28 February 2026 100 3,952 4,052
Net book value
At 28 February 2026 0 1,146 1,146
At 28 February 2025 23 2,377 2,400

4. Fixed asset investments

Other investments Total
£ £
Cost or valuation before impairment
At 01 March 2025 120 120
At 28 February 2026 120 120
Carrying value at 28 February 2026 120 120
Carrying value at 28 February 2025 120 120

5. Creditors: amounts falling due within one year

2026 2025
£ £
Trade creditors 0 136
Amounts owed to director 744 432
Accruals 1,985 1,890
2,729 2,458